-

Milliman releases 2025 report on U.S. organ and tissue transplant costs, utilization, and emerging issues

Estimated annual per member per month organ transplant costs rise 5.2% (age 65 or less) and 9.1% (ages 65+) since 2020

SEATTLE--(BUSINESS WIRE)--Milliman, Inc., a premier global actuarial consulting, risk management, and technology firm, today released its 2025 report on U.S. organ and tissue transplant costs and utilization. This comprehensive study provides valuable insight into the financial landscape and emerging trends in transplant care, including estimated transplants, lengths of hospital stay, and average annual costs per member per month (PMPM) across single organ/tissue and double-organ/tissue transplants.

The study found that for all combined organ and tissue transplants, per member costs based on billed charges saw an average annual increase of 5.2% for those under age 65, and 9.1% for those age 65 and over when compared to the 2020 report.

Among single organ or tissue transplants, double-lung transplants have the highest billed charges in the U.S., at an estimated $2.3 million dollars, followed by heart transplant ($1.9 million), single lung ($1.8 million) and intestine ($1.7 million). In terms of utilization, the study estimates over 28,000 kidney transplants will be performed in 2025 – by far the most of any organ – followed by nearly 11,000 liver transplants.

"A number of emerging issues and innovations in the transplant space, including benchmarking, fair distribution and availability of organs and tissue, living donation and bioengineering, and artificial intelligence have our attention,” said Nick Ortner, a senior consulting actuary with Milliman and co-author of the study. “Understanding costs, utilization, and the impact of new technologies can enable the healthcare industry – and consumers – to better navigate the complexities of transplant care and work toward more effective solutions.”

To read the full report, visit: https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-costs-utilization

About Milliman

Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. Visit us at milliman.com.

Contacts

Nick Ortner
Milliman, Inc.
Tel: +1 262 796 3403
Email: Nick.Ortner@milliman.com

Milliman, Inc.


Release Summary
Milliman has just released its report on estimated 2025 Organ and Tissue Transplant Costs.
Release Versions

Contacts

Nick Ortner
Milliman, Inc.
Tel: +1 262 796 3403
Email: Nick.Ortner@milliman.com

More News From Milliman, Inc.

Milliman Announces Acquisition of MorVest Capital, Expanding Leadership in Mortgage Sector and MSR Analytics

SEATTLE--(BUSINESS WIRE)--Milliman, Inc., a leading global consulting and actuarial firm, today announced the acquisition of MorVest Capital, a premier provider of mortgage servicing rights (MSR) analytics, risk management, and advisory services. This strategic move reinforces Milliman’s commitment to delivering comprehensive analytical solutions to the mortgage sector and expands its capabilities with MSR valuation, financing, hedging, and brokering. MorVest Capital, founded in 2013 and headqu...

Milliman analysis: Corporate pension funding levels rise for eighth consecutive month in November

SEATTLE--(BUSINESS WIRE)--Milliman, Inc., a premier global consulting and actuarial firm, today released its monthly Milliman 100 Pension Funding Index (PFI), which analyzes the 100 largest U.S. corporate pension plans. During November, the PFI funded ratio edged up from 107.0% at the end of October to 107.1% as of November 30. A 1-basis-point rise in discount rates, to 5.34% in November, drove this result. It shaved $3 billion from plan liabilities and offset market returns of only 0.44%. As o...

Milliman analysis: Public pension funding rises in October to highest level in study history

SEATTLE--(BUSINESS WIRE)--Milliman, Inc., a premier global consulting and actuarial firm, today released the latest results of its Public Pension Funding Index (PPFI), which analyzes data from the nation’s 100 largest public defined benefit plans. For the seventh straight month, the PPFI funded ratio improved in October, rising from 85.4% as of September 30 to 86.3% as of October 31, surpassing the previous high-water mark of 85.5% set at the end of 2021. Another month of strong investment retu...
Back to Newsroom